Last updated on December 2018

A Study to Evaluate Safety and Effects of Sotagliflozin Dose 1 and Dose 2 on Glucose Control in Patients With Type 2 Diabetes Severe Impairment of Kidney Function and Inadequate Blood Sugar Control

Brief description of study

Primary Objective:

To demonstrate the superiority of sotagliflozin dose 1 versus placebo with respect to hemoglobin A1c (HbA1c) reduction in patients with Type 2 diabetes who have inadequate glycemic control and severe renal impairment

Secondary Objectives:

  • To assess the effects of sotagliflozin dose 2 versus placebo based on change from baseline in HbA1c
  • To assess the effects of sotagloflozin doses 1 and 2 versus placebo
  • To evaluate the safety of sotagliflozin doses 1 and 2 versus placebo

Detailed Study Description

The study duration is up to 60 weeks including 4 weeks prior to randomization, 52 weeks of randomized treatment and a visit 4 weeks after completion of the randomized treatment period.

Clinical Study Identifier: NCT03242018

Contact Investigators or Research Sites near you

Start Over

Trial Transparency email recommended (Toll ...

Investigational Site Number 8405006
Ocoee, FL United States

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.